论文部分内容阅读
目的探讨白细胞介素-2(IL-2)+力尔凡对恶性肿瘤患者CD+4T细胞及Th1细胞、Th2细胞的调控作用。方法采用抗体标记流式细胞仪检测CD+4T细胞、双抗体夹心法(ELISA)检测Th1细胞和Th2细胞。38例恶性肿瘤患者使用IL-250万U皮下注射,1次/d×5d,力尔凡10mg肌肉注射,1次/d,15～21d。测定治疗前及治疗后2周、治疗后1个月的CD+4T细胞及Th1细胞、Th2细胞,用SPSS软件包行方差分析。结果治疗后CD+4T细胞有上升趋势,治疗后Th1细胞、Th2细胞和Th1/Th2同治疗前比较差异无显著性。结论该治疗剂量对提升CD+4T细胞有作用,对调控Th1+细胞和Th2细胞无明显作用,因此二者治疗的靶点应在CD+4T细胞的其他亚群。
Objective To investigate the regulatory effect of interleukin-2 (IL-2) + lervan on CD + 4T cells, Th1 cells and Th2 cells in patients with malignant tumors. Methods CD + 4T cells were detected by flow cytometry with antibody labeling and Th1 cells and Th2 cells by double antibody sandwich method. 38 cases of malignant tumor patients using IL-250 million U subcutaneous injection, 1 / d × 5d, Riehl 10mg intramuscular injection, 1 / d, 15 ~ 21d. The CD + 4T cells, Th1 cells and Th2 cells before treatment and 2 weeks after treatment and 1 month after treatment were determined by ANOVA with SPSS software package. Results After treatment, CD + 4T cells showed an upward trend. There was no significant difference in Th1 cells, Th2 cells and Th1 / Th2 before treatment after treatment. Conclusion The therapeutic dose has the effect on promoting CD + 4T cells and has no significant effect on the regulation of Th1 + cells and Th2 cells. Therefore, the target of both treatment should be in other subsets of CD + 4T cells.